Related Experiment Videos
Second generation of dopamine agonists: pros and cons
1Department of Neurology, Asaf Harofe Hospital, Zrifin, Iszael.
Journal of Neural Transmission. Supplementum
|January 1, 1995
Summary
Dopamine agonists (DAGs) offer benefits for Parkinson's disease (PD) by reducing levodopa (LD) dosage and side effects. Newer DAGs show promise in managing motor fluctuations and dyskinesias in early PD stages.
Area of Science:
- Neurology
- Pharmacology
Background:
- Dopamine agonists (DAGs) were initially explored as levodopa (LD) replacements for Parkinson's disease (PD).
- DAGs were found to reduce LD dosage and mitigate its side effects, including motor fluctuations and dyskinesias.
Purpose of the Study:
- To review the established use of older dopamine agonists in Parkinson's disease treatment.
- To present the clinical experience with three newer, promising dopamine agonists: cabergoline, ropinirole, and pramipexole.
Main Methods:
- Review of existing literature on "old" dopamine agonists.
- Presentation of clinical data and experience with newer dopamine agonists (cabergoline, ropinirole, pramipexole).
Main Results:
- Older DAGs effectively reduce levodopa (LD) dosage and associated side effects.
- DAGs help in delaying motor fluctuations and reducing dyskinesias in Parkinson's disease patients.
- Newer DAGs like cabergoline, ropinirole, and pramipexole are emerging as promising therapeutic options.
Conclusions:
- Dopamine agonists are valuable adjuncts in Parkinson's disease management, not replacements for levodopa.
- Early introduction of DAGs may delay the onset of motor complications.
- Emerging DAGs offer potential for improved treatment strategies in Parkinson's disease.